No Data
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
On November 29, Corning Jereh Pharmaceuticals-B (09966) spent 2.2756 million Hong Kong dollars to repurchase 0.6 million shares.
Kangning Jerry Pharmaceuticals-B (09966) announced that on November 29, 2024, the company invested 227 million...
Hong Kong stocks unusual | Conic Jerry Pharmaceuticals-B (09966) fell nearly 4% as institutions lowered the peak sales of Envida and KN046 after adjustment of POS economics.
Corning Incorporated Pharma-B (09966) has dropped nearly 4%, as of this report, down 3.91%, trading at 3.91 Hong Kong dollars, with a turnover of 12.9509 million Hong Kong dollars.
【Brokerage Focus】Bocom Intl lowers the target price for Corning Pharmaceutical (09966) by 32.4% due to short-term pressure on product sales.
Jingu Finance News | Bocom Intl released research reports stating that Conagenix Pharmaceuticals (09966) is in the process of forming a HER2 pipeline matrix, with huge commercial value yet to be realized: 1) Phase I data of JSKN033 was first disclosed at the SITC conference and selected for LBA, showing a DCR of 80% in NSCLC patients with HER2 expression (IHC≥ 1+) or HER2 mutation. 2) Early clinical data of JSKN003 treating platinum-resistant ovarian cancer and HER2-positive (IHC 3+) solid tumors (excluding breast cancer) were presented at the ESMO conference, with ORRs reaching
Why Investors Shouldn't Be Surprised By Alphamab Oncology's (HKG:9966) 26% Share Price Surge
Alphamab Oncology's (HKG:9966) 31% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
